Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(CSE:
MDMA
)
0.0750
UNCHANGED
Official Closing Price
Updated: 3:58 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about MDMA
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities
From
PharmAla Biotech
Via
GlobeNewswire
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities
From
PharmAla Biotech
Via
GlobeNewswire
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing
January 24, 2024
New ticker symbol goes into effect immediately
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
January 08, 2024
PharmAla to present its intellectual property assets to potential partners at the annual JPM healthcare conference on January 8-11th in San Francisco
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Begins Trading on OTCQB
September 06, 2023
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
July 31, 2023
Patent Filing Follows Year of Preclinical Research, Academic Publication
From
PharmAla Biotech
Via
GlobeNewswire
Life Science Investor Forum: Presentations Now Available for Online Viewing
June 23, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
June 20, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
June 09, 2023
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Biotech to form Australian Psychedelics Joint Venture with Vitura Health
May 01, 2023
From
PharmAla Biotech
Via
GlobeNewswire
Revive Therapeutics Secures MDMA Supply from PharmAla Biotech for MDMA Transdermal Patch Development
February 06, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023
PharmAla Biotech is the only company in the world with the ability to ship GMP MDMA and Psilocybin today
From
PharmAla Biotech
Via
GlobeNewswire
The Power Play by The Market Herald Releases New Interviews with Pharmala Biotech Holdings, Nextech AR Solutions and Enertopia Discussing Their Latest News
January 27, 2023
Via
ACCESSWIRE
KCSA Mental Health Virtual Investor Conference: Presentations Now Available for Online Viewing
December 16, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
PharmAla Completes Pre-IND Meeting with FDA, to Present at KCSA Virtual Investor Conference
December 13, 2022
Company invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation
From
Virtual Investor Conferences
Via
GlobeNewswire
KCSA Mental Health Virtual Investor Conference Agenda Announced for December 15th
December 13, 2022
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
November 16, 2022
PharmAla will be the exclusive global reseller of Mindset’s cGMP psilocybin to appropriately licensed clinical researchers
From
PharmAla Biotech
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.